Specific Efficacy and Safety in the Clinical Application of Anlotinib for Thymic Carcinoma.

Thymic carcinoma is a rare and aggressive malignancy characterized by high invasiveness, poor prognosis, and limited treatment options post-chemotherapy failure. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in inhibiting tumor growth and metastasis, suggesting potential as an adjunctive therapy in this challenging clinical setting.